PULMOFLOW INC
PharmaPULMOFLOW INC is a pharmaceutical company focused on Respiratory. Key products include KITABIS PAK.
PULMOFLOW INC's Key Drugs
PULMOFLOW INC's core commercial portfolio centers on KITABIS PAK, spanning Respiratory — its most strategically important drugs approved in the last 15 years.
PULMOFLOW INC's Recent FDA Approvals
New NDA/BLA approvals for PULMOFLOW INC over the last two years — novel drugs only, excluding generics and label supplements.
PULMOFLOW INC's Therapeutic Areas
PULMOFLOW INC's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PULMOFLOW INC's Top Competitors
PULMOFLOW INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PULMOFLOW INC Pipeline Snapshot
Active clinical trials for PULMOFLOW INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • KITABIS PAK leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-12-02
- Latest
- 2023-04-10
- Applications
- 1